导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 23.84% | 42/1219 |
| 近一周 | -0.60% | 1443/1457 |
| 近一月 | -1.30% | 1348/1446 |
| 近一季 | -1.35% | 1330/1402 |
| 近半年 | 14.67% | 58/1320 |
| 近一年 | 23.91% | 41/1210 |
| 近两年 | 23.29% | 99/1014 |
| 近三年 | 10.78% | 463/841 |
| 成立以来 | 59.30% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2025 | - - |
5.69% 36/1314 |
4.66% 36/1383 |
16.07% 44/1469 |
- - |
| 2024 | -1.18% 1058/1292 |
-7.40% 1112/1173 |
2.59% 63/1208 |
1.93% 447/1251 |
2.06% 418/1292 |
| 2023 | -9.02% 934/1121 |
5.97% 29/995 |
-2.20% 951/1035 |
-8.66% 1030/1075 |
-3.90% 1035/1121 |
| 2022 | -23.58% 748/955 |
-18.16% 754/793 |
8.62% 35/850 |
-7.93% 795/895 |
-6.63% 878/955 |
| 2021 | 25.76% 28/782 |
-3.25% 56/76 |
6.97% 24/79 |
6.66% 40/77 |
13.93% 7/782 |
| 2020 | 22.21% 32/632 |
-1.68% 40/65 |
2.44% 36/75 |
10.47% 13/76 |
9.84% 9/77 |
| 2019 | 21.62% 47/548 |
15.61% 41/1682 |
-5.11% 1663/1825 |
2.99% 37/65 |
7.64% 18/63 |
| 2018 | - - |
- - |
- - |
- - |
0.10% 1104/1542 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 国投瑞银白银期货(LOF)A | 1.7164 | 48.92% |
| 国投瑞银白银期货(LOF)C | 1.7017 | 48.76% |
| 泰信现代服务业混合 | 2.1670 | 38.91% |
| 创金合信全球医药生物股票发起(QDII)C | 1.7789 | 37.65% |
| 泰信发展主题混合 | 1.8890 | 37.48% |
| 永赢先锋半导体智选混合发起A | 1.2881 | 28.89% |
| 永赢先锋半导体智选混合发起C | 1.2863 | 28.72% |
| 易方达标普生物科技美元汇C | 0.2399 | 28.01% |
| 嘉实资源精选股票A | 4.7401 | 21.68% |
| 华商致远回报混合C | 1.6720 | 21.39% |
| 银华可转债债券 VS. () |